Canaccord Genuity analyst Max Masucci maintained a Buy rating on Natera (NASDAQ:NTRA) on Friday, setting a price target of $145, which is approximately 33.32% above the present share price of $108.76.
Masucci expects Natera to post earnings per share (EPS) of -$0.72 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Natera, with an average price target of $134.67.
The analysts price targets range from a high of $145 to a low of $118.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $98.14 million and a net profit of -$55.78 million. The company's market cap is $9.28 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 90.7% and a 85.88% success rate.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.